Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, PR China.
Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, PR China.
Int J Biol Macromol. 2020 Apr 15;149:1180-1188. doi: 10.1016/j.ijbiomac.2020.01.303. Epub 2020 Jan 31.
Ulcerative colitis (UC) is a chronic inflammatory bowel disease of unknown etiology with increasing incidence world widely. Previous studies have indicated that the α-D-glucan YCP purified from the mycelium of the marine fungus Phoma herbarum YS4108 had certain immunomodulatory activities in animal and cell models. In the study, the therapeutic effect and intestinal regulatory activity of YCP (40 mg/kg, intraperitoneal injection) on UC were investigated in dextran sulfate sodium (DSS)-induced colitis mice. The results showed YCP could improve the general symptoms, reestablish the intestinal immune balance, and repair the mucosal barrier in colitis mice. The administration of YCP also significantly increased butyrate and isovaleric acid levels. In addition, YCP resulted in prominent alterations on specific microbiota including Firmicutes, Bacteroidetes, Proteobacteria, Clostridiales, and Lachnospiraceae which are closely related to immune regulation and mucus repair. Therefore, YCP may be a candidate for curing UC because of its conspicuous effects comparable to 5-aminosalicylic acid (5-ASA).
溃疡性结肠炎（UC）是一种病因不明的慢性炎症性肠病，其发病率在世界范围内呈上升趋势。先前的研究表明，从海洋真菌 Phoma herbarum YS4108 菌丝体中纯化的α-D-葡聚糖 YCP 在动物和细胞模型中具有一定的免疫调节活性。在这项研究中，研究了 YCP（40mg/kg，腹腔注射）对葡聚糖硫酸钠（DSS）诱导的结肠炎小鼠的治疗效果和肠道调节活性。结果表明，YCP 可改善结肠炎小鼠的一般症状，重建肠道免疫平衡，修复黏膜屏障。YCP 的给药还显著增加了丁酸和异戊酸的水平。此外，YCP 导致特定微生物群的明显变化，包括与免疫调节和粘液修复密切相关的厚壁菌门、拟杆菌门、变形菌门、梭状芽孢杆菌和lachnospiraceae。因此，由于其与 5-氨基水杨酸（5-ASA）相当的显著效果，YCP 可能是治疗 UC 的候选药物。
